First Command Advisory Services Inc. Purchases 2,198 Shares of Merck & Co., Inc. (NYSE:MRK)

First Command Advisory Services Inc. boosted its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 25.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,870 shares of the company’s stock after buying an additional 2,198 shares during the period. First Command Advisory Services Inc.’s holdings in Merck & Co., Inc. were worth $1,432,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Cross Staff Investments Inc increased its holdings in Merck & Co., Inc. by 3.5% during the 4th quarter. Cross Staff Investments Inc now owns 6,710 shares of the company’s stock worth $732,000 after purchasing an additional 225 shares in the last quarter. PFW Advisors LLC bought a new stake in Merck & Co., Inc. during the 1st quarter worth approximately $212,000. Dynamic Advisor Solutions LLC grew its holdings in shares of Merck & Co., Inc. by 6.0% in the first quarter. Dynamic Advisor Solutions LLC now owns 77,833 shares of the company’s stock valued at $10,270,000 after acquiring an additional 4,433 shares in the last quarter. Kennedy Investment Group grew its holdings in shares of Merck & Co., Inc. by 16.0% in the fourth quarter. Kennedy Investment Group now owns 2,564 shares of the company’s stock valued at $280,000 after acquiring an additional 354 shares in the last quarter. Finally, Schear Investment Advisers LLC grew its holdings in shares of Merck & Co., Inc. by 16.0% in the fourth quarter. Schear Investment Advisers LLC now owns 3,233 shares of the company’s stock valued at $352,000 after acquiring an additional 445 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on MRK shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Merck & Co., Inc. in a report on Tuesday, June 18th. Argus raised Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. Wells Fargo & Company upped their target price on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a report on Wednesday, March 27th. Berenberg Bank upped their target price on Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a report on Monday, April 8th. Finally, Truist Financial upped their target price on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $133.00.

View Our Latest Stock Report on MRK

Merck & Co., Inc. Trading Up 0.2 %

NYSE:MRK opened at $126.08 on Wednesday. The company has a market cap of $319.34 billion, a P/E ratio of 140.09, a P/E/G ratio of 2.43 and a beta of 0.38. The stock’s fifty day moving average price is $128.99 and its two-hundred day moving average price is $125.39. Merck & Co., Inc. has a 1 year low of $99.14 and a 1 year high of $134.63. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The firm’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.40 earnings per share. As a group, analysts expect that Merck & Co., Inc. will post 8.62 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, July 8th. Stockholders of record on Monday, June 17th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Monday, June 17th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.44%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 342.22%.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.